[go: up one dir, main page]

Duan et al., 2019 - Google Patents

RNA‐binding motif protein 6 is a candidate serum biomarker for pancreatic cancer

Duan et al., 2019

Document ID
9729877600305316581
Author
Duan B
Hu X
Fan M
Xiong X
Han L
Wang Z
Tong D
Liu L
Wang X
Li W
Yang J
Huang C
Publication year
Publication venue
PROTEOMICS–Clinical Applications

External Links

Snippet

Purpose Early diagnosis is crucial to improve outcomes for pancreatic cancer patients (PC). The present study is designed to identify differently expressed peptides involved in PC as potential biomarkers. Experimental Design The serum proteome of 22 PC patients, 12 …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Similar Documents

Publication Publication Date Title
Stewart et al. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels
Brown et al. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue
Sofiadis et al. Proteomic profiling of follicular and papillary thyroid tumors
Duan et al. RNA‐binding motif protein 6 is a candidate serum biomarker for pancreatic cancer
Washam et al. Identification of PTHrP (12-48) as a plasma biomarker associated with breast cancer bone metastasis
Chen et al. Identification of host-immune response protein candidates in the sera of human oral squamous cell carcinoma patients
Iuga et al. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma
EP2369349A2 (en) Non-invasive in vitro method to detect transitional cell carcinoma of the bladder
Liu et al. Reduced transthyretin expression in sera of lung cancer
Yoo et al. Discovery of gastric cancer specific biomarkers by the application of serum proteomics
Cho et al. ProteinChip array profiling for identification of disease-and chemotherapy-associated biomarkers of nasopharyngeal carcinoma
Zhou et al. LC‐MS/MS‐Based Quantitative Proteomics Analysis of Different Stages of Non‐Small‐Cell Lung Cancer
Shen et al. Serum proteome profiling reveals SOX3 as a candidate prognostic marker for gastric cancer
Chen et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel‐assisted digestion and iTRAQ labeling mass spectrometry
Song et al. Identification of serum protein biomarkers in biliary atresia by mass spectrometry and enzyme‐linked immunosorbent assay
Giusti et al. Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament‐related proteins
Hoskins et al. Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation
Liu et al. Secretomes are a potential source of molecular targets for cancer therapies and indicate that APOE is a candidate biomarker for lung adenocarcinoma metastasis
Zhang et al. A prognostic biomarker for gastric cancer with lymph node metastases
Amon et al. Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer
Yang et al. Identification of novel low molecular weight serum peptidome biomarkers for non‐small cell lung cancer (NSCLC)
Ma et al. Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer
Flatley et al. MALDI MS profiling of post‐DRE urine samples highlights the potential of β‐microseminoprotein as a marker for prostatic diseases
Choong et al. Proteome-wide profiling of the MCF10AT breast cancer progression model
Wang et al. Elevated serum levels of circulating immunoinflammation-related protein complexes are associated with cancer